Skip to main content
SpringerLink
Log in

FISH detection of HER-2/neu oncogene amplification in early onset breast cancer

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

HER-2/neu (c-erbB-2) gene amplification based on Southern blotting or immunohistochemistry has been shown to be predictive of poor outcome in breast cancer occurring in women over 40, but there is little data on the role of HER-2/neu in young women with breast cancer, many of whom may have inherited BRCA1 or other predisposing genes. The present study used fluorescent in situ hybridization (FISH) on archival specimens of breast cancer from 37 women under the age of 40 to evaluate the role of HER-2/neu amplification in this cohort, and to also evaluate the efficacy of FISH for quantifying amplification. The frequency of primary tumors with a greater than fourfold increase in gene copy number was found to be 38%, which is similar to the frequency of amplification reported in Southern blot studies in older women. However, the greater sensitivity of FISH enabled detection of low level amplification (more than 2 but less than 8 gene copies), which was found in an additional 30% of the tumors. Patients with low level amplification demonstrated a 54% recurrence rate, compared to 86% in those with high amplification and 17% in those with no amplification. HER-2/neu amplification appeared to be more prognostic of recurrence than nodal status, with 45% of node negative tumors recurring compared to 62% of those which were node positive, nor was tumor size predictive of recurrence in this cohort since tumors of 2 cm or less recurred in 44% of cases compared to 57% of those larger than 2 cm. Thus, this study demonstrates that FISH is a reproducible and sensitive technique for detecting HER-2/neu amplification, and that amplification of the oncogene is the strongest independent indicator of recurrence of breast cancer in young women.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182, 1987

    PubMed  Google Scholar 

  2. Klijn JG, Berns EM, Bontenbal M, Foekens J: Cell biological factors associated with the response of breast cancer to systemic treatment. Cancer Treatment Reviews 19 (Supplement B): 45–63, 1993

    Google Scholar 

  3. Paterson MC, Dietrich KD, Danyluk J, Paterson AH, Lees AW, Jamil N, Hanson J, Jenkins H, Krause BE, McBlain WA, Slamon DJ, Fourney RM: Correlation between c-erbB-2 amplification and risk of recurrent disease in nodenegative breast cancer. Cancer Research 51: 556–567, 1991

    PubMed  Google Scholar 

  4. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712, 1989

    PubMed  Google Scholar 

  5. Garcia I, Dietrich PY, Aapro M, Vauthier G, Vadas L, Engel E: Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. Cancer Research 49: 6675–6679, 1989

    PubMed  Google Scholar 

  6. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk G, Godolphin W, Sliwkowski M, Akita R, Paterson MC, Slamon DJ: HER-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Research 53: 4960–4970, 1993

    PubMed  Google Scholar 

  7. Molina R, Ciocca DR, Tandon AK, Allred DC, Clark GM, Chamness GC, Gullick WJ, McGuire WL: Expression of HER-2/neu oncoprotein in human breast cancer: A comparison of immunohistochemical and western blot techniques. Anticancer Research 12(6B): 1965–1971, 1992

    PubMed  Google Scholar 

  8. Descotes F, Pavy JJ, Adessi GL: Human breast cancer: Correlation study between HER-2/neu amplification and prognostic factors in an unselected population. Anticancer Research 13: 119–124, 1993

    PubMed  Google Scholar 

  9. Babiak J, Hugh J, Poppema S: Significance of c-erbB-2 amplification and DNA aneuploidy. Cancer 70: 770–776, 1992

    PubMed  Google Scholar 

  10. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koemer F, Cirrincione CT, Budman DR, Wood WC, Barcos M: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. New Eng J Med 330: 1260–1266, 1994

    PubMed  Google Scholar 

  11. Wolman SR, Pauley RJ, Mohamed AN, Dawson PJ, Visscher DW, Sarker FH: Genetic markers as prognostic indicators in breast cancer. Cancer 70 (Supplement): 1765–1774, 1992

    PubMed  Google Scholar 

  12. Prost S, Le MG, Douc-Rasy S, Ahomadegbe JC, Spielmann M, Guerin M, Riou G: Association of c-erbB2-gene amplification with poor prognosis in non-inflammatory breast carcinomas but not in carcinomas of the inflammatory type. Int J Cancer 58: 763–768, 1994

    PubMed  Google Scholar 

  13. Press MF, Hung G, Godolphin W, Slamon DJ: Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54: 2771–2777, 1994

    PubMed  Google Scholar 

  14. Farkas DH, McMahon LW, Cai P, Umek RM: Improved quantitation of HER-2/neu gene copy number in breast tumor-derived DNA samples. Am J Clin Path 100: 444–450, 1993

    PubMed  Google Scholar 

  15. Dati C, Muraca R, Tazartes O, Antoniotti S, Perroteau I, Giai M, Cortese P, Sismondi P, Saglio G, De Bortoli M: c-erb-2 and ras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome. Int J Cancer 47: 833–838, 1991

    PubMed  Google Scholar 

  16. Pechoux C, Chardonnet Y, Noel P: Immunohistochemical studies on c-erbB-2 oncoprotein expression in paraffin embedded tissues in invasive and non-invasive human breast lesions. Anticancer Res 14: 1343–1360, 1994

    PubMed  Google Scholar 

  17. Mansour EG, Ravdin PM, Dressler L: Prognostic factors in early breast carcinoma. Cancer 74(Supplement): 381–400, 1994

    PubMed  Google Scholar 

  18. Hankey BF, Miller B, Curtis R, Kosary C: Trends in breast cancer in younger women in contrast to older woman. Journal of the National Cancer Institute Monographs (16): 7–14, 1994

  19. Swanson GM, Lin CS: Survival patterns among younger women with breast cancer: the effects of age, race, stage, and treatment. Journal of the National Cancer Institute Monographs (16): 69–77, 1994

  20. Bowcock AM: Molecular cloning of BRCA1: a gene for early onset familial breast and ovarian cancer. Breast Cancer Research and Treatment 28: 121–135, 1993

    PubMed  Google Scholar 

  21. Bischoff FZ, Hansen MF: Genetics of familial breast cancer. The Cancer Bulletin 45: 476–482, 1993

    Google Scholar 

  22. Easton D, Ford D, Peto J: Inherited susceptibility to breast cancer. Cancer Surveys 18: 95–113, 1993

    PubMed  Google Scholar 

  23. Albain KS, Allred DC, Clark GM: Breast cancer outcome and predictors of outcome: are there age differentials? Journal of the National Cancer Institute Monographs (16): 35–42, 1994

  24. de la Rochefordiere A, Asselain B, Campana F, Scholl SM, Fenton J, Vilcoq JR, Durand JC, Pouillart P, Magdelenat H, Fourquet A: Age as prognostic factor in premenopausal breast carcinoma. Lancet 341: 1039–1043, 1993

    PubMed  Google Scholar 

  25. Lee W, Han K, Harris CP, Meisner LF: Detection of aneuploidy and possible deletion in paraffin-embedded rhabdomyosarcoma cells with FISH. Cancer Genetics and Cytogenetics 68: 99–103, 1993

    PubMed  Google Scholar 

  26. Imyanitov EN, Chernitsa OI, Serova OM, Nikoforova IF, Pluzhnikova GF, Knyazev PG: Amplification of HER-2/neu (erbB-2/neu) oncogene as the most significant prognostic factor in a group of Russian breast cancer patients. Neoplasma 40: 35–39, 1993

    PubMed  Google Scholar 

  27. Watatani M, Nagayama K, Imanishi Y, Kurooka K, Wada T, Inui H, Hirai K, Ozaki M, Yasutomi M: Genetic alterations on chromosome 17 in human breast cancer: relationships to clinical features and DNA ploidy. Breast Cancer Research and Treatment 28: 231–239, 1993

    PubMed  Google Scholar 

  28. Nagai MA, Marques LA, Torloni H, Brentani MM: Genetic alterations in c-erbB-2 protooncogene as prognostic markers in human primary breast tumors. Oncology 50: 412–417, 1993

    PubMed  Google Scholar 

  29. Lee W, Han K, Drut RM, Harris CP, Meisner LF: Use of FISH for retrospective detection of aneuploidy in multiple myeloma. Genes Chromosomes and Cancer 7: 137–143, 1993

    PubMed  Google Scholar 

  30. Han K, Lee W, Harris CP, Kim W, Shim S, Meisner LF: Quantifying chromosome changes and lineage involvement in myelodysplastic syndrome (MDS) using fluorescent in situ hybridization (FISH). Leukemia 8: 81–86, 1994

    PubMed  Google Scholar 

  31. Allred DC, Clark GM, Elledge CR, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. Journal of the National Cancer Institute 85: 200–206, 1993

    PubMed  Google Scholar 

  32. Elledge RM, Allred DC: The p53 tumor suppressor gene in breast cancer. Breast Cancer Research and Treatment 32: 39–47, 1994

    PubMed  Google Scholar 

  33. King MC, Rowell S: Genetic analysis of breast and ovarian cancer in families. In: Dickson RB, Lippman ME (eds) Mammary Tumorigenesis and Malignant Progression. Kluwer Academic Publishers, Boston/Dordrecht/London, 1994, p 51

    Google Scholar 

  34. Keyhani-Rofagha S, O'Toole RV, Farrar WB, Sickle-Santanello B, DeCenzo J, Young D: Is DNA ploidy an independent prognostic indicator in infiltrative node-negative breast adenocarcinoma? Cancer 65: 1577–1581, 1990

    PubMed  Google Scholar 

  35. Gilchrist KW, Gray R, van Driel-Kulker A, Mesker WE, Ploem-Zaaijer JJ, Ploem JS, Taylor SG, Tormey DC: High DNA content and prognosis in lymph node positive breast cancer. A case control study by the university of Leiden and ECOG. Breast Cancer Research and Treatment 28: 1–8, 1993

    PubMed  Google Scholar 

  36. Batsakis JC, Sneige N, el-Naggar AK: Flow cytometric (DNA content and S-phase fraction) analysis of breast cancer. Cancer 71 (Supplement): 2152–2153, 1993

    Google Scholar 

  37. Witzig TE, Ingle JN, Cha SS, Schaid DJ, Tabery RL, Wold LE, Grant C, Gonchoroff NJ, Katzmann JA: DNA ploidy and the percentage of cells in S-phase as prognostic factors for women with lymph node negative breast cancer. Cancer 74: 1752–1761, 1994

    PubMed  Google Scholar 

  38. Loprinzi CL, Ravdin PM, Laurentiis M, Novotny P: Do American oncologists know how to use prognostic variables for patients with newly diagnosed primary breast cancer? Journal of Clinical Oncology 12: 1422–1426, 1994

    PubMed  Google Scholar 

  39. McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl Med 326: 1756–1761, 1992

    Google Scholar 

  40. McGuire WL, Tandon AK, Allred DC, Chamness GC, Ravdin PM, Clark GM: Prognosis and treatment decisions in patients with breast cancer without axillary node involvement. Cancer 70 (Supplement): 1775–1781, 1992

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Evaluation Centre for the Toxicology of Fertility Regulating Drugs, Shanghai, People's Republic of China

    Wei-Rong Xing

  2. Department of Pathology, University of Wisconsin Medical School, Madison, Wisconsin, USA

    Kennedy W. Gilchrist & Lorraine F. Meisner

  3. Department of Preventive Medicine, University of Wisconsin Medical School, Madison, Wisconsin, USA

    Lorraine F. Meisner

  4. University of Wisconsin Medical School, Madison, Wisconsin, USA

    Wilner Samson & Lorraine F. Meisner

  5. State Laboratory of Hygiene, Cytogenetics Section, Madison, Wisconsin, USA

    Charles P. Harris & Lorraine F. Meisner

Authors
  1. Wei-Rong Xing
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kennedy W. Gilchrist
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Charles P. Harris
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wilner Samson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lorraine F. Meisner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xing, WR., Gilchrist, K.W., Harris, C.P. et al. FISH detection of HER-2/neu oncogene amplification in early onset breast cancer. Breast Cancer Res Tr 39, 203–212 (1996). https://doi.org/10.1007/BF01806187

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01806187

Key words

Search

Navigation